|
Match
|
Document |
Document Title |
|
|
7384734 |
Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
The present invention provides an approach for developing an algorithm for determining the effectiveness of anti-viral drugs based on a comprehensive analysis of paired phenotypic and genotypic...
|
|
|
7384637 |
Drug for AIDS treatment
Raising the T-cell count in an HIV positive patient having a low T-cell count by orally administering an effective amount of a composition containing a material obtained by treating whole human...
|
|
|
7378515 |
Synthetic gagpol genes and their uses
The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The...
|
|
|
7378490 |
Cyclic peptides and aids vaccines
Cyclic peptides comprising, as a constituent chain or chains, one or two amino acid sequences selected from the groups consisting of the amino acid sequence Glu-Ala-Asp-Asp-Arg and the amino acid...
|
|
|
7361459 |
Antiviral inhibition of capsid proteins
Methods for evaluating the antiviral activity of test compounds are provided. Further aspects of the methods involve the retroviral capsid protein of HIV-1. In another aspect, methods of reducing...
|
|
|
7351412 |
Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA
This invention is in the field of lymphadenopathy virus, which has been designated Human Immunodeficiency Virus (HIV). This invention relates to a diagnostic means and method to detect the presence...
|
|
|
7348136 |
Method and device for detecting feline immunodeficiency virus
A method and device for determining a feline immunodeficiency virus infection or vaccination in an animal. The method includes contacting a biological sample from a felid with various FIV...
|
|
|
7335365 |
HIV-encoded chemoattractant
The combination of HIV proteins Tat and Nef is chemotactic for CD4+ cells. Utilizing the capacity of Tat and Nef to modulate CD4+ cell trafficking and infiltration, the invention provides various...
|
|
|
7318927 |
Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
The invention relates to HIV chimeric gene formed by the union of fragments of different genes of said virus, wherein said fragments contains epitopes for cytotoxic T cells (CTL) or HIV-1 auxiliary...
|
|
|
7311916 |
Methods of eliciting broadly neutralizing antibodies targeting HIV-1 gp41
The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is...
|
|
|
7306804 |
HIV-specific T-cell induction
This invention discloses diagnostic, preventative, and treatment therapies of AIDS involving determining whether a subject exhibits an HLA-Cw7-restricted CTL response. Some methods are directed to...
|
|
|
7297784 |
DNA encoding T-1249 and other viral fusion inhibitor peptides useful for treating aids
The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core...
|
|
|
7291337 |
Peptide having an affinity for gp120
The peptide in this invention is a peptide having affinity to gp120 represented by Formula (1): H-A1-A2-A3-A4-A5-R(SEQ ID No. 1)
(in the formula,
H means hydrogen, A1 is aspartic...
|
|
|
7285271 |
Antigenic composition comprising an HIV gag or env polypeptide
Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome,...
|
|
|
7276333 |
Viral infection inhibitor targeting integrase N-terminal domain
The object of the present invention is to provide a screening method of a new integrase inhibitor being able to inhibit an HIV infection before the reverse transcription step and having a...
|
|
|
7276242 |
Vipox vector coding an HIV antigen and a cytokine
The invention relates to a fowl pox virus encoding an HIV antigen (gag and/or pol) and a cytokine (γ-interferon).
|
|
|
7273695 |
HIV immunoassays using synthetic envelope polypeptides
Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome,...
|
|
|
7273614 |
Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of...
|
|
|
7262270 |
Fusion protein construct and method for inducing HIV-specific serum IgG and secretory IgA antibodies in-vivo
The present invention provides a fusion protein construct (gp41HA) consisting of the ectodomain of the HIV-1 IIIB envelope glycoprotein gp41 fused to a fragment of the influenza virus HA2...
|
|
|
7255862 |
ALVAC/FIV constructs
Recombinants containing and expressing lentivirus, retrovirus or immunodeficiency virus DNA and methods for making and using the same are disclosed and claimed. In an exemplified embodiment,...
|
|
|
7232685 |
Cell lines with latent immunodeficiency virus and methods of use thereof
The present invention provides isolated cells that comprise, integrated into the genome of the cell, a transcription-competent immunodeficiency virus or a transcription-competent immunodeficiency...
|
|
|
7226598 |
Peptide inhibitors of HIV entry
Described herein are chimeric peptides comprising a soluble trimeric coiled-coil and all or a portion of the N-peptide region of HIV gp41. These molecules are stable, trimeric coiled-coils that...
|
|
|
7220826 |
Expressing gp140 fragment of primary HIV-1 isolate
A vector for eliciting an immune response to a host comprising a gene encoding the gp140 protein of the primary isolate of HIV-1, BX08, under the control of a promotor for expression of the protein...
|
|
|
7195768 |
Polyvalent immunogen
The present invention relates, generally, to a polyvalent immunogen and, more particularly, to a method of inducing neutralizing antibodies against HIV and to a polyvalent immunogen suitable for...
|
|
|
7179468 |
Antigen for developing neutralizing antibodies to human immunodeficiency virus
The present invention provides polypeptides comprising a stabilized trimer of the carboxyl-terminal core region of the ectodomain of an enveloped virus, such as HIV. A subject polypeptide comprises...
|
|
|
7157225 |
Nucleotide sequences of HIV-1 type (or subtype) O retrovirus antigens
An HIV-1 type (or subtype) O retrovirus protein, or a natural or synthetic polypeptide or peptide including at least a part of said protein, which is capable of being recognised by antibodies...
|
|
|
7153509 |
Immunogenic peptides comprising a T-helper epitope and a B-cell neutralizing antibody epitope
The present invention relates, generally, to a polyvalent immunogen and, more particularly, to a method of inducing neutralizing antibodies against HIV and to a polyvalent immunogen suitable for...
|
|
|
7138119 |
Compositions and methods for inhibition of HIV-1 infection
This invention provides a composition which comprises an admixture of three compounds, wherein: (a) one compound is an antibody which binds to a CCR5 receptor; (b) one compound retards attachment...
|
|
|
7122190 |
Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids
The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of...
|
|
|
7118751 |
DNA vaccines encoding antigen linked to a domain that binds CD40
Vaccines that target one or more antigens to a cell surface receptor improve the antigen-specific humoral and cellular immune response. Antigen(s) linked to a domain that binds to a cell surface...
|
|
|
7115363 |
Retrovirus capable of causing AIDS, means and methods for detecting it in vitro
The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers...
|
|
|
7105164 |
HIV-specific cytotoxic T-cell responses
A method of generating an HIV-specific cytotoxic T-cell response in a host involves an initial administration of a T-helper molecule to the host to prime T-helper cells of the immune system of the...
|
|
|
7097971 |
HIV-1 peptide, antigen, immunogenic composition, diagnostic method and immunoassay kit
The present invention comprises novel and modified peptides capable of inducing a HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective...
|
|
|
7097841 |
Ferritin fusion proteins for use in vaccines and other applications
An isolated ferritin fusion protein is provided in which ferritin is fused with a protein or peptide capable of being fused to ferritin without interfering with the polymeric self-assembly of the...
|
|
|
7094408 |
Immunogenicity using a combination of DNA and vaccinia virus vector vaccines
This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral...
|
|
|
7094405 |
Peptides which elicit a high neutralizing antibody titer, cytotoxic T lymphocyte response and T helper cell response in a broad range of MHC type recipients
Peptide constructs comprised of multideterminant T helper peptides from the envelope glycoprotein of HIV previously identified to induce proliferative responses in four different haplotypes of mice...
|
|
|
7090851 |
Long lasting fusion peptide inhibitors of viral infection
Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107...
|
|
|
7090848 |
HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response
The present invention relates to HIV-1 envelope proteins from a donor with non-progressive HIV-1 infection whose serum contains broadly cross-reactive, primary virus neutralizing antibody. The...
|
|
|
7087375 |
Method for determining the mechanism of HIV RT inhibitors
The present invention is directed to the field of HIV resistance to RT inhibitors and methods of determining the levels and mechanisms of action of HIV resistance. The methods of the present...
|
|
|
7078516 |
NUCLEOTIDE SEQUENCES DERIVED FROM THE GENOME OF RETROVIRUSES OF THE HIV-1, HIV-2 AND SIV TYPE, AND THEIR USES IN PARTICULAR FOR THE AMPLIFICATION OF THE GENOMES OF THESE RETROVIRUSES AND FOR THE IN VITRO DIAGNOSIS OF THE DISEASES DUE TO THESE VIRUSES
The invention provides oligonucleotide primers selected from the group consisting of a nucleotide sequence of the gag, vpr, and pol genes of HIV-1 Bru, HIV-1 Mal, HIV-1 Eli, HIV-2 ROD, and SIV MAC;...
|
|
|
7078039 |
Immunogenic composition
The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to an HLA-based HIV vaccine.
|
|
|
7078038 |
Gp120 mutants and biological applications
An isolated and purified human immunodeficiency virus type 1 (HIV-1) mutant gp120 envelope glycoprotein containing an amino acid mutation in position 112 which contains replacement of W with S,...
|
|
|
7071322 |
HIV envelope polynucleotides and immunogenic composition
Oligonucleotide sequences encoding gp120 polypeptides from breakthrough isolates of vaccine trials using MN-rgp120 and the encoded gp120 polypeptides are provided. Use of the gp120 polypeptides...
|
|
|
7070787 |
Method of inducing the production of antibodies to HIV
The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also...
|
|
|
7067246 |
Method for determining prognosis of HIV infected individuals
The serum levels of anti-tat antibodies, tat protein, and p24 protein are predictive of disease progression in HIV infected individuals and serve as prognostic markers. The present invention...
|
|
|
7067134 |
HIV vaccine
A novel HIV vaccine is provided. In particular, the vaccine comprises an avirulent and non-cytolytic recombinant HIV wherein the NSS of the virus' envelope glycoprotein is replaced with a...
|
|
|
7063849 |
Use of HIV-1 gp120 and gp160 proteins modified in the v3 loop for the preparation of vaccine compositions and formulations containing the same
Use of HIV-1 gp120 and gp160 proteins which have been modified in the V3 loop for preparing vaccine compositions and formulations containing them which induce a systemic and mucosal immunity. Use...
|
|
|
7056656 |
Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
This invention relates to the use of oligourea molecules to specifically inhibit protein-nucleic acid interactions. In particular, it provides an oligourea molecule that competes with the Tat...
|
|
|
7056519 |
Methods for inducing HIV-neutralizing antibodies
The present invention relates to a method for inducing antibodies neutralizing HIV primary isolates in a mammal, comprising administration of a pharmaceutical composition comprising a polypeptide...
|
|
|
7053175 |
Synthetic peptides useful in biological assays for detecting infections caused by group O HIV-1 viruses
Synthetic peptides of the monomer type with 13 to 33 amino acids, in linear form or in a form cyclized by means of inter-cysteine disulphide bridges, have the general formula (I):
...
|